Header Logo

Connection

SHUBHAM PANT to Antibodies, Bispecific

Back to Details
This is a "connection" page, showing publications SHUBHAM PANT has written about Antibodies, Bispecific.
SHUBHAM PANT
Connection Strength
0.168
Antibodies, Bispecific
  1. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022 Dec; 23(12):1558-1570.
    View in: PubMed
    Score: 0.168
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.